<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51760">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655030</url>
  </required_header>
  <id_info>
    <org_study_id>CR-BD-RCT</org_study_id>
    <nct_id>NCT01655030</nct_id>
  </id_info>
  <brief_title>Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Creatine Monohydrate as Adjunctive Therapy for Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether creatine monohydrate is effective as an
      adjuvant treatment for bipolar depression.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MADRS (Montgomery-Asberg depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDRS-17 (Hamilton Depression Rating Scale - 17-item version)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>CGI (Clinical Global Impressions Scale) - Severity and Improvement</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>YMRS (Young Mania Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Bipolar I Disorder</condition>
  <condition>Current Episode Depressed</condition>
  <arm_group>
    <arm_group_label>creatine monohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6g qd for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6g qd for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>creatine monohydrate</intervention_name>
    <arm_group_label>creatine monohydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals eligible for the study will be adults aged 18 to 60 years of age who met
             DSM-IV criteria assessed by the SCID (Structural Clinical Interview for DSM-IV) for
             type I bipolar disorder, current episode depressed.

          -  Patients who have scored &gt; 19 on the Montgomery-Asberg Depression Rating Scale
             (MADRS) will be included, although more than two weeks of treatment with lithium
             (serum level&gt; 0.8 mEq / L), valproate (serum levels&gt; 50 mg / L) or quetiapine
             (300-600mg/dia dose) or drug combination.

          -  Antipsychotics, anticonvulsants, benzodiazepines, and thyroid supplementation will be
             allowed if the dose has remained stable over the past two weeks.

          -  Antidepressants will be allowed if the dosage has remained stable for 4 weeks.

        Exclusion Criteria:

          -  Subjects with substance abuse within 2 weeks before inclusion or substance dependence
             up to 2 months will not be included.

          -  Other exclusion criteria will be:

               -  diagnosis of schizophrenia,

               -  dementia,

               -  delirium,

               -  epilepsy,

               -  mental retardation,

               -  clinically unstable medical illnesses,

               -  preexisting renal disease,

               -  history of hypersensibility to creatine.

          -  Not included are individuals at high risk for suicidal or homicidal behavior or
             self-mutilation will not be included.

          -  Women with gestational potential can only be included if they are using reliable
             contraception.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beny Lafer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bipolar Disorder Research Program, Coordinator, IPq-HC-FMUSP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Toniolo, MD</last_name>
    <phone>55 11 26617928</phone>
    <email>ricardo.toniolo@uol.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Psychiatry - HC-FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01060-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 7, 2013</lastchanged_date>
  <firstreceived_date>July 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ricardo Alexandre Toniolo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
